Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
RESEARCH TOOLSreports
Arvinas Holding Company (ARVN) Stock Price & Analysis
761 Followers
ARVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.57 - $53.08
Previous Close$32.33
Volume686.04K
Average Volume (3M)724.42K
Market Cap
$2.27B
Enterprise Value$954.60M
Total Cash (Recent Filing)$1.26B
Total Debt (Recent Filing)$3.20M
Price to Earnings (P/E)-5.5
Beta1.63
Next Earnings
Aug 06, 2024EPS Estimate
-$1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.93
Shares Outstanding68,431,891
10 Day Avg. Volume558,672
30 Day Avg. Volume724,424
Standard Deviation0.39
R-Squared0.07
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.25
Price to Sales (P/S)28.18
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.16
Enterprise Value/Gross Profit12.16
Enterprise Value/Ebitda-2.54
Forecast
1Y Price Target
$65.25Price Target Upside96.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Arvinas Holding Company News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressVepdestrant-palbociclib combination data show improvement in median PFS in ESR1 mutant patients, adding to the drug's competitive profile.
Financial StrengthThe company's financial position is strong, with sufficient cash to fund operations well into the future, indicating stability and reduced financial risk.
Strategic PartnershipsThe partnership deal for ARV-766 is seen as solid, potentially allowing the company to focus on its early-stage pipeline and add value to its stock.
Bears Say
Clinical TrialsThere is uncertainty in trial timing due to the event-driven primary endpoint of VERITAC-2, although enrollment is on track.
Market CompetitionCompetitor data in 2024 could impact ARVN's market position, with LLY's imlunestrant presenting potential competition.
Stock ValuationPrice Target decreased due to dilution following a private placement.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $13.57 and its highest was $53.08 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Currently, no data Available
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Aug 06, 2024 which is in 82 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on May 07, 2024. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.42 by $0.45.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -$1.17.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 68,431,890 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.42. Following the earnings report the stock price went up 6.417%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Among the largest hedge funds holding Arvinas Holding Company’s share is New Leaf Venture Partners, L.L.C.. It holds Arvinas Holding Company’s shares valued at 53M.
---
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.25 (96.51% Upside)
$65.25 (96.51% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $484.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.84%
12-Months-Change
Fundamentals
Return on Equity
-63.32%
Trailing 12-Months
Asset Growth
3.13%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
---
ARVN Stock 12 Month Forecast
Average Price Target
$65.25
▲(96.51% Upside)
Technical Analysis
Best Analysts Covering ARVN
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+24.52%
initiated a buy rating 9 days ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +24.52% per trade.
---